Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

If you have ATTR-CM, you may benefit from additional support beyond what your doctors provide. Transthyretin cardiac amyloidosis (ATTR-CM), an incurable condition that involves a buildup of irregular ...

Novo Nordisk acquired the worldwide rights to Prothena’s ATTR amyloidosis business and pipeline in July 2021. Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion upon ...

Intellia Therapeutics has temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z, a CRISPR-based therapy for transthyretin amyloidosis with ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in the wings -- choosing one has become a new challenge, with softer endpoints ...

Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...